33 results about "Uric acid excretion" patented technology

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

The invention discloses a walnut-derived xanthine oxidase inhibitory peptide and application thereof, and belongs to the technical field of bioactive peptide biology. The amino acid sequence of the xanthine oxidase inhibitory peptide provided by the invention is as shown in SEQ ID No. 1. Through in-vitro activity determination, the IC50 value of the inhibitory peptide is 3.34 mg / mL, and it is proved that the inhibitory peptide has high inhibitory activity on xanthine oxidase. Besides, the inhibitory peptide can reduce the levels of creatinine, urea nitrogen, adenosine deaminase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, regulate the expression of kidney uric acid resorption protein URAT1, uric acid excretion protein GLUT9 and ABCG2, and significantly reduce the generation of uric acid, can be used for inhibiting xanthine oxidase and preventing or improving hyperuricemia, is applied to preparation of drugs for improving hyperuricemia, and has broad application prospects. The medicine takes the active peptide as the only active ingredient or one of the active ingredients, and has a good application prospect.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

The application belongs to the technical field of biological medicine engineering, and particularly relates to application of hypoxia-inducible factor-1 alpha as a target in development or screening of a drug for preventing and treating hyperuricemia, and proposes that hypoxia-inducible factor-1 alpha as a target is applied in development or screening of a drug for preventing and treating hyperuricemia, and the drug can ubiquitinate and degrade hypoxia-inducible factor-1 alpha. Hypoxia-inducible factor-1 alpha can act on xanthine oxidase for generating uric acid, promote generation of uric acid, or regulate vascular endothelial growth factor through hypoxia-inducible factor-1 alpha, cause damage to intestinal epithelial cells and renal tubular epithelial cells, and then inhibit expression of uric acid excretion transporter protein ATP binding cassette subfamily G member 2, and reduce excretion of uric acid. Therefore, hyperuricemia can be effectively prevented and treated, side effects are reduced, and the life quality of patients is improved.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an LXH-2301 pharmaceutical composition and application of the LXH-2301 pharmaceutical composition in preparation of a medicine for treating gout with hyperuricemia. The LXH-2301 pharmaceutical composition disclosed by the invention comprises the following components: (a) LXH-2301 tablets with the specification of 0.5 g / tablet; (b) febuxostat tablets with the specification of 20 mg / tablet; wherein the LXH-2301 tablet is administered three times a day, two tablets are administered each time, the total dosage is 1.0 g, and the LXH-2301 tablet is combined with the febuxostat tablet for use. Patients suitable for the composition need to simultaneously meet the following screening standards: morning urine pHlt; and 6.0. The LXH-2301 pharmaceutical composition provided by the invention is applied to the preparation of medicines for treating gout with hyperuricemia, and the limitation of insufficient curative effect on patients with uric acid poor excretion type gout is solved; the problem of lack of prevention means for uric acid crystallization kidney injury is solved.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

The invention discloses a traditional Chinese medicine extract composition for assisting in reducing uric acid and a preparation method, and relates to the technical field of traditional Chinese medicine compositions, the traditional Chinese medicine extract composition comprises poria cocos, cichorium intybus, radix puerariae, gentiana macrophylla, rhizoma smilacis glabrae, Tibetan capillary, emblic leafflower fruit, glabrous sarcandra herb, Chinese starjasmine stem, wild buckwheat rhizome and white gourd. The traditional Chinese medicine extract composition breaks through the limitation of single existing uric acid reducing mechanism, plays a role in uric acid generation and excretion links, regulates a key pathway of uric acid metabolism through traditional Chinese medicine components to reduce uric acid generation, promotes urination to promote uric acid excretion, inhibits inflammatory mediator release and relieves oxidative damage by means of glabrous sarcandra herb and wild buckwheat rhizome components, and has a good application prospect. According to the traditional Chinese medicine preparation, the effect of multi-link synergistic effect of reducing uric acid, resisting inflammation and resisting oxidation is achieved, meanwhile, the blood uric acid level is reduced, the gout arthralgia symptom is relieved, the problem that an existing traditional Chinese medicine preparation cannot give consideration to comprehensive curative effect is solved, the requirement of a patient for comprehensive improvement of the illness state is met, and the overall effectiveness of treatment is improved.

The invention provides a spleen-invigorating, dampness-eliminating and turbidity-discharging formula and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-60 parts of rhizoma smilacis glabrae, 5-20 parts of pyrrosia lingua, 5-25 parts of yam rhizome, 10-50 parts of lysimachia christinae hance, 5-15 parts of achyranthes bidentata, 10-30 parts of pearl barley, 5-15 parts of endive, 1-10 parts of rhizoma atractylodis, 1-10 parts of golden cypress and 5-25 parts of The spleen-invigorating, dampness-eliminating and turbidity-eliminating prescription can reduce the activity of xanthine oxidase and adenosine deaminase in liver tissues, inhibit the generation of uric acid, regulate the expression of an intestinal and kidney urate transporter, reduce uric acid reabsorption and increase uric acid excretion, plays a role in protecting kidney organs while reducing uric acid, and does not cause damage to the liver structure. The spleen-invigorating, dampness-eliminating and turbidity-eliminating formula has a good application prospect in preparation of medicines for preventing and / or treating hyperuricemia.

The application belongs to the technical field of biochemistry, and particularly relates to a rice residue short peptide and application thereof in reducing uric acid, wherein the amino acid sequence of the rice residue short peptide is any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 10. The rice residue short peptide can realize simultaneous intervention of multiple links of uric acid metabolism, has the characteristics of inhibiting uric acid generation, promoting uric acid excretion and antioxidation, can realize excellent uric acid reduction effect, and provides further theoretical basis for deep development of rice processing by-products.

The present invention belongs to the field of drug synthesis, and in particular relates to a URAT1-inhibiting aromatic acyl nuciferine derivative and its preparation method and application. The present invention structurally modifies nuciferine by introducing an active group, thereby improving the biological activity of nuciferine in lowering uric acid. Cell experiments have found that the aromatic acyl nuciferine derivative prepared by the present invention can inhibit the expression of URAT1 in HK-2 cells, promote uric acid excretion, thereby reducing uric acid levels, which is of great significance for the further development of new URAT1 inhibitors. The aromatic acyl nuciferine derivative with uric acid-lowering and kidney-protecting effects provided by the present invention has a simple synthesis method, low raw material price, and novel structure.

The invention relates to the field of microorganisms. Specifically, the Hungata bacteria provided by the invention can metabolize uric acid in a culture medium, part of the bacteria can completely metabolize about 2000 [mu] g / mL of uric acid in the culture medium within 8 h, and meanwhile, in-vivo experiments also show that the content of uric acid in serum, urine and excrement of different hyperuricemia model mice can be remarkably reduced, gout is reduced, and the Hungata bacteria can be used for treating hyperuricemia. Pathological injuries of kidneys and intestinal tracts of hyperuricemia mice are relieved, organ functions are protected, pains of patients are reduced, uric acid excretion is promoted, the level of serum uric acid is reduced, intestinal barrier is maintained, intestinal environment is protected, and health of the mice is promoted. Therefore, the Hungata bacterium provided by the invention can hopefully replace or partially replace the existing compound medicine, and has a wide application prospect.

The invention relates to a dihydroquinazolinone compound as well as a preparation method and application thereof. The dihydroquinazolinone compound has an excellent inhibiting effect on GLUT9, can effectively inhibit the activity of GLUT9 so as to promote uric acid excretion, further achieves the effect of reducing uric acid, and can be used for treating diseases related to the activity or expression quantity of GLUT9. The dihydroquinazolinone compound or the pharmaceutically acceptable salt thereof has no obvious toxicity to organs, and can significantly reduce renal injury caused by hyperuricemia and relieve gout symptoms.

The invention discloses a functional hydrogen water formula capable of promoting uric acid excretion of gout, the functional hydrogen water formula comprises the following components: hydrogen, purified water, sodium bicarbonate, a magnesium ion compound and a vitamin C derivative, the dissolution concentration of the hydrogen in water is 0.8-2.0 mg / L, the addition amount of the sodium bicarbonate is 0.5-3.0 g / L, the concentration of the magnesium ion compound is 10-50 mg / L in terms of magnesium element, the concentration of the vitamin C derivative is 10-50 mg / L in terms of magnesium element, and the concentration of the vitamin C derivative is 0.5-1.0 mg / L. The addition amount of the vitamin C derivative is 0.1-1.0 g / L. The functional hydrogen water can accurately promote uric acid excretion, the serum uric acid (SUA) is reduced by 43.9% (216.3 + / -20.7 [mu] mol / L) compared with a model group and the urinary uric acid (UUA) is increased by 90.7% (238.9 + / -19.8 [mu] mol / 24h) in 24 hours after the functional hydrogen water intervenes in a hyperuricemia rat for 21 days, and the functional hydrogen water is superior to common hydrogen water and can be comparable to benzbromarone. The mechanism is as follows: sodium bicarbonate adjusts the pH value to 7.5-8.5 to help to dissolve urate, magnesium + hydrogen down-regulates URAT1 (reduced by 46.5%), up-regulates GLUT9 (increased by 93.1%) to reduce uric acid reabsorption, and also improves the activity of liver uricase (increased by 61.1%) to assist decomposition, so that a multi-channel excretion promoting system is formed.

The invention provides a model for high and low uric acid excretion fraction classification of gout patients, and relates to the technical field of biology. The DNA methylation marker comprises 18 methylation sites, beta values of the 18 methylation sites are used as input characteristics of the model to construct a model for classifying uric acid excretion fractions of gout patients, and the model has good prediction performance.

The application belongs to the technical field of biological medicine, and relates to saRNA for promoting expression of ABCG2 gene and application thereof; saRNA targeting ABCG2 gene is designed for the first time, including human ABCG2 saRNA, which is saRNA-1', saRNA-2', mouse ABCG2 saRNA, which is saRNA-1, saRNA-2; by transfecting saRNA into cells, high expression of ABCG2 gene is realized in human and mouse renal tubular epithelial cells; and through UA efflux experiments at the cell level and in a mouse model, it is proved that improving the expression of ABCG2 gene can promote the efflux of UA in cells, and the excretion of uric acid in blood to urine; an experimental basis is provided for preparing small RNA drugs for treating hyperuricemia or gout with ABCG2 as a target.

The invention discloses a pharmaceutical composition capable of regulating and reducing uric acid and balancing internal secretion as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a bifunctional fusion polypeptide XUR-01 and an IL1beta TNF alpha bispecific monoclonal antibody. The fusion polypeptide is formed by sequentially connecting a xanthine oxidase inhibition domain, a GLUT9 transporter inhibition domain and an endocrine regulation domain in series through flexible connecting peptides, and the complete sequence of the fusion polypeptide is shown as SEQ ID NO: 1. The sequences of variable regions of a heavy chain and a light chain of the bispecific antibody are respectively shown as SEQ ID NO: 2 and SEQ ID NO: 3. The preparation synchronously realizes comprehensive effects of inhibiting generation of uric acid, promoting excretion of uric acid, neutralizing key inflammatory factors and regulating endocrine balance through a multi-target synergistic mechanism, and shows a treatment effect obviously superior to that of a single-target drug and good safety in treatment of hyperuricemia and related metabolic disorders. The invention overcomes the defects of single effect and large side effect of the existing medicine, and can be used for treating hyperuricemia with endocrine disorder, kidney injury or inflammation related diseases.

The invention discloses application of an AKK PROBIO strain in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. Effective methods for treating hyperuricemia with small side effects in the prior art are still limited. In order to solve the problem, the invention provides an AKK PROBIO strain, and the preservation number of the AKK PROBIO strain is CGMCC (China General Microbiological Culture Collection Center) No.20955. The bacterium can obviously reduce the serum uric acid level of a hyperuricemia mouse, the curative effect of the bacterium is derived from a multi-system synergistic effect mechanism, the intestinal-renal axis steady state can be recovered, and hyperuricemia is improved through the following four key ways: (1) inhibiting uric acid biosynthesis; (2) the excretion of kidney uric acid is enhanced; (3) inflammation and oxidative stress reaction can be relieved; and (4) reconstructing intestinal flora balance.

The invention discloses a medicinal and edible composite plant solid beverage for assisting in reducing uric acid and a preparation method of the medicinal and edible composite plant solid beverage. According to the medicinal and edible composite plant solid beverage, in-vitro uric acid reducing activity and sensory scores of a fuzzy mathematical model are subjected to equal weight by adopting comprehensive scores, and a formula is optimized by adopting a response surface method. The obtained formula extract comprises 0.50 g of mint, 1.10 g of lotus leaf, 2.00 g of dandelion, 2.00 g of composite powder for adjusting taste and 3.00 g of composite powder for promoting uric acid excretion, and the xanthine oxidase inhibition rate is 84.02 + / -0.15%. An in-vitro anti-oxidation experiment proves that the solid beverage has an anti-oxidation effect. In-vivo experiments prove that the solid beverage has the effect of promoting uric acid excretion by obviously reducing blood uric acid, serum creatinine level and uric acid excretion coefficient of a model mouse; the activity of xanthine oxidase in vivo can be reduced, and the effect of inhibiting uric acid synthesis is achieved; meanwhile, the activity of glutathione peroxidase and superoxide dismutase is improved, and the antioxidant activity is achieved. The product is a medicinal and edible solid beverage and shows wide market potential.

This invention discloses the application of aspirin eugenol ester in the preparation of drugs for improving hyperuricemia. While maintaining the pharmacological activities of aspirin and eugenol, aspirin eugenol ester shields the carboxyl group of aspirin, reducing the gastrointestinal irritation and other side effects of aspirin upon ingestion. Simultaneously, it overcomes the irritating odor and instability of eugenol, enabling it to exert therapeutic effects in improving hyperuricemia. Through multiple pathways, including inhibiting uric acid production, promoting uric acid excretion, activating antioxidant pathways, and inhibiting inflammatory and apoptotic signals, it significantly reduces serum uric acid levels in hyperuricemic rats, thereby improving hyperuricemia.

The invention discloses a medicinal and edible composition with the effects of resisting oxidation and reducing uric acid and application of the medicinal and edible composition. The medicinal and edible composition is mainly prepared from the following components in parts by weight: 6 to 12 parts of tricholoma matsutake modified polysaccharide, 15 to 25 parts of rehmannia iridoid glycoside extract, 15 to 25 parts of fructus forsythiae phenylethanoid glycoside extract and 15 to 25 parts of sophora flower bud polyphenol extract. Through verification, the medicinal and edible composition disclosed by the invention has good oxidation resistance, can remarkably inhibit generation of uric acid, promote excretion of uric acid and reduce blood uric acid, and is beneficial to prevention or alleviation of gout. Therefore, the medicinal and edible composition with the effects of resisting oxidation and reducing uric acid can be applied to preparation of functional foods, health care products or medicines for reducing uric acid.